- Home
- AGIO vs SBET Comparison
AGIO vs SBET Comparison
Compare AGIO & SBET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | SBET |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AGIO | SBET |
|---|---|---|
| Price | $30.08 | $7.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $37.63 | $21.00 |
| AVG Volume (30 Days) | 623.7K | ★ 5.3M |
| Earning Date | 04-30-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,011,000.00 | $28,055,000.00 |
| Revenue This Year | $71.05 | $109.16 |
| Revenue Next Year | $163.65 | $14.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 666.04 |
| 52 Week Low | $22.24 | $0.19 |
| 52 Week High | $46.00 | $124.12 |
Technical Indicators
Market Signals| Indicator | AGIO | SBET |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 43.71 |
| Support Level | $26.48 | $6.10 |
| Resistance Level | $30.90 | $8.34 |
| Average True Range (ATR) | 0.97 | 0.37 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 98.65 | 2.31 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SBET SharpLink Gaming Ltd.
SharpLink Gaming Inc is one of the world's largest publicly traded companies to adopt ETH as its primary treasury reserve asset - a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world's smart-contract platform and second largest digital asset.